Scott Morenstein

Scott Morenstein is a Managing Director and Portfolio Manager at CAM Capital where he has led the firm's investment strategy in both private and public biotech companies since 2013. CAM Capital was established in 2012 by Bruce Kovner following his retirement from Caxton Associates, the macro hedge fund he founded and managed from 1983 to 2011. CAM Capital manages assets exclusively for entities related to Mr. Kovner and its senior employees. Prior to joining CAM Capital in 2013, Mr. Morenstein was a Partner at Valence Advantage Life Sciences Fund and Principal at Caxton Advantage Venture Partners, life science focused venture capital firms affiliated with Caxton Associates, which he joined in 2007. Prior to Caxton Advantage, Scott was an investment banker and research analyst at Seaview Securities and Lehman Brothers from 2000-2005. Mr. Morenstein served as a Director of and CAM was the largest investor in Celator Pharmaceuticals until its acquisition by Jazz Pharmaceuticals. He was nominated a Director of Synta Pharmaceuticals to advise the company as it explored strategic alternatives ultimately leading to a merger with Madrigal Pharmaceuticals. He served as a member of Gemin X Pharmaceutical's Board until its acquisition by Cephalon. He currently serves as a Director of Molecular Templates (Nasdaq: MTEM), Palvella Therapeutics, Antios Therapeutics (private) and Velicept Therapeutics (private). Mr. Morenstein received an MBA from Harvard Business School and a BA from the University of Pennsylvania in the Biological Basis of Behavior with a concentration in the Physiology of Neural Systems.